Related Experiment Video

Updated: Aug 8, 2026

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
11:35

Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)

Published on: August 21, 2016

EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients

Sarah R Sabir1, Sharon Yeoh2, George Jackson3

  • 1Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK. s.sabir@leeds.ac.uk.

Cancers
|September 6, 2017
PubMed

Insights

The discovery of echinoderm microtubule associated protein-like 4 - anaplastic lymphoma kinase (EML4-ALK) variants in lung cancer has revolutionized targeted therapy. Understanding these variants is key to improving patient response to ALK inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The fusion of echinoderm microtubule associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) in lung adenocarcinomas, known as EML4-ALK, was discovered in 2007.
  • Over 15 EML4-ALK variants have been identified in lung cancers, significantly impacting molecular-targeted therapy.
  • The identification of EML4-ALK fusions has led to a paradigm shift in treating lung cancer patients.

Purpose of the Study:

  • To investigate how specific EML4-ALK variants influence the biological and molecular characteristics of cancer cells.
  • To identify the critical signaling pathways activated by different EML4-ALK variants.
  • To explore the correlation between EML4-ALK variant type and patient response to anaplastic lymphoma kinase (ALK) therapy.

Main Methods:

  • Review of existing literature on EML4-ALK variants and their associated signaling pathways.
  • Analysis of data linking specific EML4-ALK variants to clinical outcomes and therapeutic responses.
  • Comparative study of molecular and biological properties across different EML4-ALK variants.

Main Results:

  • Different EML4-ALK variants exhibit distinct effects on cancer cell biology and molecular signaling.
  • The specific EML4-ALK variant present in a patient influences their response to ALK-targeted therapies.
  • Understanding variant-specific signaling is crucial for predicting treatment efficacy.

Conclusions:

  • The type of EML4-ALK variant is a critical determinant of therapeutic response in lung cancer patients.
  • Further research into EML4-ALK variants and their signaling pathways can optimize personalized treatment strategies.
  • Continued investigation holds promise for developing more effective and specific therapies for lung cancer.
Keywords:
anaplastic lymphoma kinaseechinoderm microtubule-associated proteinnon-small cell lung cancertyrosine kinase inhibitor

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Genetic Variant Detection in the CALR gene using High Resolution Melting Analysis08:46

Genetic Variant Detection in the CALR gene using High Resolution Melting Analysis

Published on: August 26, 2020

Related Concept Videos

Ligand Binding and Linkage00:49

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
Smooth Endoplasmic Reticulum01:21

Smooth Endoplasmic Reticulum

Smooth endoplasmic reticulum or smooth ER is a sub-organelle with specialized functions in animal cells and plant cells. It is often associated with the tubule morphology of the endoplasmic reticulum.
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...